Pediatric Vaccines Market

Paediatric Vaccine Market: Pneumococcal Indication Segment Anticipated to Be the Most Attractive Segment Through 2026: Global Industry Analysis and Opportunity Assessment, 2016-2026

Ask The Analyst Customization Available Request Methodology

Global Paediatric Vaccine Market: Towards a better and safer tomorrow

Paediatric vaccines are administered to a child in its paediatric age which is from 0 – 18 years of age. Vaccines are generally given in order to prevent children from diseases transferred through infections, seasonal variations and even through unhygienic areas. Depending upon disease, the vaccines are administered at regular intervals.  WHO has designed a standard immunization program in order to have desired time interval between vaccines doses.

Paediatric vaccines considered in the report include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. Pneumococcal vaccine is administered to prevent the child from infectious diseases such as pneumonia. DTP vaccines is a combination vaccine administered against prevention of three diseases those are diphtheria, tetanus and pertussis. Hib vaccine is also a combination vaccine for hepatitis B and influenza and is widely accepted.

The market to expand manifold during the forecast period (2016 - 2026)

In terms of revenue, the global paediatric vaccine market is projected to expand at a CAGR of 12.2% during the forecast period and is expected to be valued at US$ 88.14 Bn by the end of 2026.

Revamped government policies to benefit the market, though soaring prices of vaccines to play spoilsport

The growth of the global paediatric vaccine market is primarily driven by increasing awareness regarding benefits of vaccination in prevention of diseases, rising economic growth, the collaboration of national manufacturers with key players in view to provide high-quality vaccines in at remote areas and initiative by global key players in developing innovative vaccines. In addition favourable reimbursement and increasing government support is expected to fuel the market growth over the forecast period. However, rising cost of vaccines, low accessibility to remote areas and increasing the availability of biosimilars at low rates might hinder the market growth over the forecast period.

The Pneumococcal segment to act as a catalyst in the overall market growth

Based on indication, the global paediatric vaccine market is segmented into pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine and meningococcal vaccine. In terms of revenue share, the pneumococcal segment dominated the global paediatric vaccine market in 2015 and is expected to reach the cusp within the forecast period. The Hib segment is expected to witness relatively higher growth rates in terms of value in the global paediatric vaccine market over the forecast period.

Recombinant segment to face steep competition from the Conjugate segment within the forecast period

Based on technology, the global paediatric vaccine market is segmented into live or attenuated vaccine, inactivated or killed vaccines, conjugate vaccine, toxoid vaccine, subunit vaccine and recombinant vaccine. In terms of revenue share, the conjugate segment dominated the global paediatric vaccine market in 2015 and is expected to maintain the spike throughout the forecast period, registering higher CAGR as compared to the recombinant segment.

Monovalent vaccine segment to accumulate maximum market share

Based on vaccine type, the global paediatric vaccine market is segmented into monovalent vaccines and multivalent vaccines. Among these, monovalent vaccine segment held maximum market share in 2015 and expected to continue the trend throughout the forecast period.

The Institutional Health Centres segment to topple Hospital Pharmacy segment in the forecast period

Based on end user, the global paediatric vaccine market is segmented into hospital pharmacies, retail pharmacies and institutional health centres. Currently, institutional health centres segment accounts for relatively higher revenue share, followed by hospital pharmacy end user segment.

paediatric vaccine market_Image for preview analysis

North America market to lead the pack

The global paediatric vaccine market is segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, APEJ (Asia Pacific excluding Japan), Japan and the Middle East & Africa (MEA). In terms of value, North America is expected to be the dominant regional market by 2016 end and is expected to expand at a CAGR of 11.0% over the forecast period. APEJ is expected to be the fastest growing market in terms of revenue growth in the global paediatric vaccine market, registering a CAGR of 14.9% over the forecast period.

Key stakeholders to create clamour in the market through mergers and revamped investment policies

Some key players in the global paediatric vaccine market included in this report are GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., Sanofi, Panacea Biotec, Zydua Cadila, Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Bharat Biotech and Indian Immunologicals Ltd.

Future Market Insights offers a 10-year forecast for the global paediatric vaccine market. The primary objective of the report is to offer updates and information related to market opportunities in the global dermatology devices market.

Report Description

The primary objective of the report is to offer insights on the market dynamics that can influence growth of the global paediatric vaccine market over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global paediatric vaccine market are presented in the report.

To understand and assess opportunities in this market, the report offers market forecast on the basis of indication, technology, vaccine type, end user and regions. The report provides analysis of the global paediatric vaccine market in terms of market value (US$ Mn).

Market Segmentation

Region

 

Technology

 

Indication

 

End User

 

Vaccine Type

 

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • APEJ

  • MEA

  • Japan

  • Live or Attenuated Vaccine

  • Inactivated or Killed Vaccine

  • Toxoid Vaccine

  • Conjugate Vaccine

  • Subunit Vaccine

  • Recombinant Vector Vaccine

  • Pneumococcal Conjugate Vaccine

  • DTP Vaccine

  • Influenza

  • Meningococcal Vaccine

  • Polio Vaccine

  • Rotavirus Vaccine

  • MMR Vaccine

  • Varicella Virus Vaccine

  • Hospital Pharmacies

  • Retail Pharmacies

  • Institutional Health Centres

  • Monovalent Vaccines

  • Multivalent Vaccines

 

The report begins with the market definition, followed by definitions of the different indication of paediatric vaccine. The market dynamics section includes a comprehensive analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global paediatric vaccine market.

The next section of the report analyses the global paediatric vaccine market on the basis of technology and presents forecast in terms of value for the next 10 years. In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global paediatric vaccine market.

In the final section of the report, a ‘competitive landscape’ has been included to provide a dashboard view of key companies operating in the global paediatric vaccine market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global paediatric vaccine market and the potential players. However, this section also includes market strategies and SWOT analysis of the main players operational in the global paediatric vaccine market. Detailed profiles of paediatric vaccine manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies.

What is our research methodology?

To deduce the market size of the global paediatric vaccine market, we have considered various viewpoints based on secondary research. Furthermore, data points such as regional split and market split in terms of services and parts, service provider, and vehicle type; and qualitative inputs from industry experts have been considered to arrive at suitable market estimates. The forecast presented in the report evaluates the actual revenue generated and expected revenue in the global paediatric vaccine market over the forecast period.

When developing the market forecast, the report begins with sizing the current market, which forms the basis for forecasting how the market is expected to grow during the forecast period. Given the characteristics of the market, we have triangulated the data on the basis of various analyses based on supply side, demand side, and other dynamics of the global paediatric vaccine market. Also, we understand the ever-fluctuating nature of the global economy and hence, we not only conduct forecasts in terms of CAGR, but also evaluate the market on the basis of key parameters such as year-on-year (Y-o-Y) growth to understand the predictability of the market and to identify growth opportunities for market players operating in the global paediatric vaccine market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is usually overlooked, while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by paediatric vaccine market. To understand key segments in terms of their growth and performance in the global paediatric vaccine market, Future Market Insights has developed a market attractiveness index. The resulting index would help providers identify existing market opportunities.

Analyst's Pick

Communicate and Connect

Secondary research plays a pivotal role in this research as the market is huge and it is constantly evolving with new innovations. We as a team not only searched for relevant information, but also spoke with some of the top honchos of vaccine manufacturing companies spread across the major healthcare economies of the world. This fetched some crucial and updated information about the market and provided a larger canvas to the research.

The striking point

The entire paediatric vaccine market is expected to surge within the forecast period. The North American region will lead the global growth of the paediatric vaccine market. But the blanket ban on MMR combination vaccine in Japan will have a massive impact on the market.

Combination vaccine: A new ray of hope 

The combination vaccine is holding the key to growth for the global paediatric vaccine market. The combination vaccine will slash the rising cost of vaccines and it will also expand the global periphery of the paediatric vaccine market.  

Pediatric Vaccines Market Reports - Table of Contents

1. Executive Summary

2. Market Introduction

2.1. Market Definition

2.2. Market Taxonomy

2.3. Parent / Associated Market Overview

3. Global Paediatric Vaccine Market Analysis Scenario

3.2. Market Size (US$ Mn) and Forecast

3.2.1. Market Size and Y-o-Y Growth

3.2.2. Absolute $ Opportunity

3.3. Market Overview

3.3.1. Value Chain

4. Market Dynamics

4.1. Macro-economic Factors

4.2. Drivers

4.2.1. Supply Side

4.2.2. Demand Side

4.3. Restraints

4.4. Opportunity

4.5. Forecast Factors – Relevance and Impact

4.6. Key Industry Events

4.7. PESTLE Analysis

5. Global Paediatric Vaccine Market Analysis and Forecasts, By Indication 

5.1. Introduction

5.2. Basis Point Share (BPS) Analysis By Indication Type

5.3. Y-o-Y Growth Projections By Indication Type

5.4. Market Value (US$ Mn) Forecast By Indication, 2016–2026

5.4.1. Pneumococcal vaccine

5.4.2. DTP vaccine

5.4.3. Rotavirus vaccine 

5.4.4. MMR vaccine

5.4.5. Polio vaccine

5.4.6. Influenza vaccine 

5.4.7. Hepatitis B vaccine

5.4.8. Meningococcal vaccine

5.4.9. Hib vaccine

5.4.10. Varicella vaccine 

5.5. Prominent Trends

5.6. Market Attractiveness By Indication 

6. Global Paediatric Vaccine Market Analysis and Forecasts, By Technology 

6.1. Introduction

6.2. Basis Point Share (BPS) Analysis By Technology 

6.3. Y-o-Y Growth Projections By Technology

6.4. Market Value (US$ Mn) Forecast By Technology, 2016–2026

6.4.1. Live or attenuated vaccine

6.4.1.6. Inactivated or killed vaccine

6.4.2.3. Toxoid vaccine

6.4.3.3. Conjugate Vaccine

6.4.4.3. Subunit vaccine

6.4.4.4. Recombinant vaccine

6.5. Prominent Trends

6.6. Market Attractiveness By Technology

7. Global Paediatric Vaccine Market Analysis and Forecasts, By Vaccine Type 

7.1. Introduction

7.2. Basis Point Share (BPS) Analysis By Vaccine Type 

7.3. Y-o-Y Growth Projections By Vaccine Type 

7.4. Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

7.4.1. Monovalent vaccine

7.4.2. Mulitvalent vaccine 

7.5. Prominent Trends

7.6. Market Attractiveness By Vaccine Type 

8. Global Paediatric Vaccine Market Analysis and Forecasts, By End Users 

8.1. Introduction

8.2. Basis Point Share (BPS) Analysis By End Users 

8.3. Y-o-Y Growth Projections By End Users 

8.4. Market Value (US$ Mn) Forecast By End Users, 2016–2026

8.4.1. Hospital Pharmacies 

8.4.2. Retail pharmacies 

8.4.3. Institutional health centers 

8.5. Prominent Trends

8.6. Market Attractiveness By End Users 

9. Global Paediatric Vaccine Market Analysis and Forecasts, By Region

9.1. Basis Point Share (BPS) Analysis By Region

9.2. Y-o-Y Growth Projections By Region

9.3. Market Value (US$ Mn) Forecast By Region

9.3.1. North America 

9.3.2. Latin America 

9.3.3. Western Europe 

9.3.4. Eastern Europe 

9.3.5. APEJ 

9.3.6. Japan 

9.3.7. MEA 

9.4. Market Attractiveness By Region

10. North America Paediatric Vaccine Market Analysis and Forecast

10.1.Introduction

10.1.1. Basis Point Share (BPS) Analysis By Country

10.1.2. Y-o-Y Growth Projections By Country

10.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

10.2.1. Pneumococcal vaccine

10.2.2. DTP vaccine

10.2.3. Rotavirus vaccine 

10.2.4. MMR vaccine

10.2.5. Polio vaccine

10.2.6. Influenza vaccine 

10.2.7. Hepatitis B vaccine

10.2.8. Meningococcal vaccine

10.2.9. Hib vaccine

10.2.10. Varicella vaccine 

10.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

10.3.1. Live or attenuated vaccine

10.3.1.1. Inactivated or killed vaccine

10.3.1.2. Toxoid vaccine

10.3.1.3. Conjugate Vaccine

10.3.1.4. Subunit vaccine

10.3.1.5. Recombinant vaccine

10.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

10.4.1. Monovalent vaccine

10.4.2. Mulitvalent vaccine 

10.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

10.5.1. Hospital Pharmacies 

10.5.2. Retail pharmacies 

10.5.3. Institutional health centers 

10.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

10.6.1. US

10.6.2. Canada

10.7.Market Attractiveness Analysis 

10.7.1. By Indication 

10.7.2. By Technology

10.7.3. By Vaccine Type 

10.7.4. By End Users 

10.7.5. By Country

10.8. Prominent Trends 

10.9. Drivers and Restraints: Impact Analysis 

11. Latin America Paediatric Vaccine Market Analysis and Forecast

11.1.Introduction

11.1.1. Basis Point Share (BPS) Analysis By Country

11.1.2. Y-o-Y Growth Projections By Country

11.1.3. Key Regulations

11.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

11.2.1. Pneumococcal vaccine

11.2.2. DTP vaccine

11.2.3. Rotavirus vaccine 

11.2.4. MMR vaccine

11.2.5. Polio vaccine

11.2.6. Influenza vaccine 

11.2.7. Hepatitis B vaccine

11.2.8. Meningococcal vaccine

11.2.9. Hib vaccine

11.2.10. Varicella vaccine 

11.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

11.3.1. Live or attenuated vaccine

11.3.1.1. Inactivated or killed vaccine

11.3.1.2. Toxoid vaccine

11.3.1.3. Conjugate Vaccine

11.3.1.4. Subunit vaccine

11.3.1.5. Recombinant vaccine

11.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

11.4.1. Monovalent vaccine

11.4.2. Mulitvalent vaccine 

11.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

11.5.1. Hospital Pharmacies 

11.5.2. Retail pharmacies 

11.5.3. Institutional health centers 

11.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

11.6.1. Brazil

11.6.2. Mexico

11.6.3. Rest of Latin America

11.7.Market Attractiveness Analysis 

11.7.1. By Indication 

11.7.2. By Technology

11.7.3. By Vaccine Type 

11.7.4. By End Users 

11.7.5. By Country

11.8. Prominent Trends 

11.9. Drivers and Restraints: Impact Analysis 

12. Western Europe Paediatric Vaccine Market Analysis and Forecast

12.1.Introduction

12.1.1. Basis Point Share (BPS) Analysis By Country

12.1.2. Y-o-Y Growth Projections By Country

12.1.3. Key Regulations

12.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

12.2.1. Pneumococcal vaccine

12.2.2. DTP vaccine

12.2.3. Rotavirus vaccine 

12.2.4. MMR vaccine

12.2.5. Polio vaccine

12.2.6. Influenza vaccine 

12.2.7. Hepatitis B vaccine

12.2.8. Meningococcal vaccine

12.2.9. Hib vaccine

12.2.10. Varicella vaccine 

12.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

12.3.1. Live or attenuated vaccine

12.3.1.1. Inactivated or killed vaccine

12.3.1.2. Toxoid vaccine

12.3.1.3. Conjugate Vaccine

12.3.1.4. Subunit vaccine

12.3.1.5. Recombinant vaccine

12.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

12.4.1. Monovalent vaccine

12.4.2. Mulitvalent vaccine 

12.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

12.5.1. Hospital Pharmacies 

12.5.2. Retail pharmacies 

12.5.3. Institutional health centers 

12.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

12.6.1. UK

12.6.2. France

12.6.3. Germany

12.6.4. Italy

12.6.5. Spain

12.6.6. Benelux

12.6.7. Rest of Western Europe

12.7.Market Attractiveness Analysis 

12.7.1. By Indication 

12.7.2. By Technology

12.7.3. By Vaccine Type 

12.7.4. By End Users 

12.7.5. By Country

12.8. Prominent Trends 

12.9. Drivers and Restraints: Impact Analysis 

13. Eastern Europe Paediatric Vaccine Market Analysis and Forecast

13.1.Introduction

13.1.1. Basis Point Share (BPS) Analysis By Country

13.1.2. Y-o-Y Growth Projections By Country

13.1.3. Key Regulations

13.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

13.2.1. Pneumococcal vaccine

13.2.2. DTP vaccine

13.2.3. Rotavirus vaccine 

13.2.4. MMR vaccine

13.2.5. Polio vaccine

13.2.6. Influenza vaccine 

13.2.7. Hepatitis B vaccine

13.2.8. Meningococcal vaccine

13.2.9. Hib vaccine

13.2.10. Varicella vaccine 

13.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

13.3.1. Live or attenuated vaccine

13.3.1.1. Inactivated or killed vaccine

13.3.1.2. Toxoid vaccine

13.3.1.3. Conjugate Vaccine

13.3.1.4. Subunit vaccine

13.3.1.5. Recombinant vaccine

13.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

13.4.1. Monovalent vaccine

13.4.2. Mulitvalent vaccine 

13.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

13.5.1. Hospital Pharmacies 

13.5.2. Retail pharmacies 

13.5.3. Institutional health centers 

13.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

13.6.1. Russia

13.6.2. Poland

13.6.3. Rest of Eastern Europe

13.7.Market Attractiveness Analysis 

13.7.1. By Indication 

13.7.2. By Technology

13.7.3. By Vaccine Type 

13.7.4. By End Users 

13.7.5. By Country

13.8. Prominent Trends 

13.9. Drivers and Restraints: Impact Analysis 

14. APEJ Paediatric Vaccine Market Analysis and Forecast

14.1.Introduction

14.1.1. Basis Point Share (BPS) Analysis By Country

14.1.2. Y-o-Y Growth Projections By Country

14.1.3. Key Regulations

14.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

14.2.1. Pneumococcal vaccine

14.2.2. DTP vaccine

14.2.3. Rotavirus vaccine 

14.2.4. MMR vaccine

14.2.5. Polio vaccine

14.2.6. Influenza vaccine 

14.2.7. Hepatitis B vaccine

14.2.8. Meningococcal vaccine

14.2.9. Hib vaccine

14.2.10. Varicella vaccine 

14.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

14.3.1. Live or attenuated vaccine

14.3.1.1. Inactivated or killed vaccine

14.3.1.2. Toxoid vaccine

14.3.1.3. Conjugate Vaccine

14.3.1.4. Subunit vaccine

14.3.1.5. Recombinant vaccine

14.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

14.4.1. Monovalent vaccine

14.4.2. Mulitvalent vaccine 

14.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

14.5.1. Hospital Pharmacies 

14.5.2. Retail pharmacies 

14.5.3. Institutional health centers 

14.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

14.6.1. China

14.6.2. India

14.6.3. Australia & New Zealand

14.6.4. ASEAN

14.6.5. Rest of APEJ

14.7.Market Attractiveness Analysis 

14.7.1. By Indication 

14.7.2. By Technology

14.7.3. By Vaccine Type 

14.7.4. By End Users 

14.7.5. By Country

14.8. Prominent Trends 

14.9. Drivers and Restraints: Impact Analysis 

15. Japan Paediatric Vaccine Market Analysis and Forecast

15.1.Introduction

15.1.1. Basis Point Share (BPS) Analysis By Country

15.1.2. Y-o-Y Growth Projections By Country

15.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

15.2.1. Pneumococcal vaccine

15.2.2. DTP vaccine

15.2.3. Rotavirus vaccine 

15.2.4. MMR vaccine

15.2.5. Polio vaccine

15.2.6. Influenza vaccine 

15.2.7. Hepatitis B vaccine

15.2.8. Meningococcal vaccine

15.2.9. Hib vaccine

15.2.10. Varicella vaccine 

15.3.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

15.3.1. Live or attenuated vaccine

15.3.1.1. Inactivated or killed vaccine

15.3.1.2. Toxoid vaccine

15.3.1.3. Conjugate Vaccine

15.3.1.4. Subunit vaccine

15.3.1.5. Recombinant vaccine

15.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

15.4.1. Monovalent vaccine

15.4.2. Mulitvalent vaccine 

15.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

15.5.1. Hospital Pharmacies 

15.5.2. Retail pharmacies 

15.5.3. Institutional health centers 

15.6.Market Attractiveness Analysis 

15.6.1. By Indication 

15.6.2. By Vaccine Type 

15.6.3. By Vaccine Type 

15.6.4. By End Users 

15.7. Prominent Trends 

15.8. Drivers and Restraints: Impact Analysis 

16. MEA Paediatric Vaccine Market Analysis and Forecast

16.1.Introduction

16.1.1. Basis Point Share (BPS) Analysis By Country

16.1.2. Y-o-Y Growth Projections By Country

16.1.3. Key Regulations

16.2.Market Value (US$ Mn) Forecast By Indication, 2016–2026

16.2.1. Pneumococcal vaccine

16.2.2. DTP vaccine

16.2.3. Rotavirus vaccine 

16.2.4. MMR vaccine

16.2.5. Polio vaccine

16.2.6. Influenza vaccine 

16.2.7. Hepatitis B vaccine

16.2.8. Meningococcal vaccine

16.2.9. Hib vaccine

16.2.10. Varicella vaccine 

16.3.Market Value (US$ Mn) Forecast By Technology, 2016–2026

16.3.1. Live or attenuated vaccine

16.3.1.1. Inactivated or killed vaccine

16.3.1.2. Toxoid vaccine

16.3.1.3. Conjugate Vaccine

16.3.1.4. Subunit vaccine

16.3.1.5. Recombinant vaccine

16.4.Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

16.4.1. Monovalent vaccine

16.4.2. Mulitvalent vaccine 

16.5.Market Value (US$ Mn) Forecast By End Users, 2016–2026

16.5.1. Hospital Pharmacies 

16.5.2. Retail pharmacies 

16.5.3. Institutional health centers 

16.6.Market Value (US$ Mn) Forecast By Country, 2016–2026

16.6.1. GCC Countries

16.6.2. South Africa

16.6.3. Rest of MEA

16.7.Market Attractiveness Analysis 

16.7.1. By Indication 

16.7.2. By Technology

16.7.3. By Vaccine Type 

16.7.4. By End Users 

16.7.5. By Country

16.8. Prominent Trends 

16.9. Drivers and Restraints: Impact Analysis 

17. Competition Landscape

17.1. Competition Dashboard

17.2. Market Share Analysis By Company (2015)

17.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)

17.3.1. GlaxoSmithKline Plc.

17.3.2. Merck & Co., Inc.

17.3.3. Pfizer Inc.

17.3.4. Sanofi

17.3.5. Pancea Biotec

17.3.6. Zydua Cadila 

17.3.7. Emergent BioSolutions Inc.

17.3.8. Serum Institute of India Pvt. Ltd.

17.3.9. Bharat Biotech 

17.3.10. Indian Immunologicals Ltd.

18. Assumptions and Acronyms Used

19. Research Methodology

Pediatric Vaccines Market Reports - List of Tables

Table 01: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2015–2026

Table 02: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2015–2026

Table 03: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2015–2026

Table 04: Global Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2015–2026

Table 05: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 06: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 07: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 08: North America Balloon Catheter Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 09: North America Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 10: Latin America Pediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 11: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 12: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 13: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 14: Latin America Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 15: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 16: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 17: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 18: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 19: Eastern Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 20: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 21: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 22: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 23: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 24: Western Europe Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 25: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 26: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 27: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 28: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 29: Asia Pacific Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 30: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 31: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 32: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 33: Japan Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Table 34: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By Country, 2016–2026

Table 35: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By Technology, 2016–2026

Table 36: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By Vaccine Type, 2016–2026

Table 37: Middle East and Africa Pediatric Vaccine Market Value (US$ Mn) Forecast By Indication, 2016–2026

Table 38: Middle East and Africa Paediatric Vaccine Market Value (US$ Mn) Forecast By End Users, 2016–2026

Pediatric Vaccines Market Reports - List of Figures

Figure 1: Global Paediatric Vaccine Market Value (US$ Mn) Forecast, 2015–2026 

Figure 2: Global Paediatric Vaccine Market Absolute $ Opportunity, 2015–2026 

Figure 3: Global Paediatric Vaccine Market Y-o-Y Growth, 2015–2026 

Figure above highlights market value, absolute $ opportunity, and Y-o-Y growth rate of the global pediatric vaccine market

Figure 4: Global Paediatric Vaccine Market – Scenario Forecast, 2016–2026 (US$ Mn)

Figure 5: Global Paediatric Vaccine Market share Analysis 2016, By Indication

Figure 6: Global Paediatric Vaccine Market share Analysis 2016, By Vaccine Type 

Figure 7: Global Paediatric Vaccine Market share Analysis 2016, By Technology 

Figure 8: Global Paediatric Vaccine Market Share Analysis (%) By Indication, 2016 & 2026

Figure 9: Global Paediatric Vaccine Market Y-o-Y Growth (%) By Indication, 2016–2026 

Figure 10: Global Paediatric Vaccine Market Y-o-Y Growth (%) By Indication, 2016–2026 

Figure 11: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Pneumococcal Segment, 2016–2026

Figure 12: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By DTP Vaccine Segment, 2016–2026

Figure 13: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Rotavirus Vaccine Segment, 2016–2026

Figure 14: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By MMR Vaccine Segment, 2016–2026

Figure 15: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Polio Vaccine Segment, 2016–2026

Figure 16: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Influenza Vaccine  Segment, 2016–2026

Figure 17: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Hepatitis B Vaccine  Segment, 2016–2026

Figure 18: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Meningococcal Vaccine Segment, 2016–2026

Figure 19: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Hib Vaccine Segment, 2016–2026

Figure 20: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Varicella Vaccine Segment, 2016–2026

Figure 21: Global Paediatric Vaccine Market Share Analysis (%) By Indication, 2016 & 2026

Figure 22: Global Paediatric Vaccine Market Y-o-Y Growth (%) By technology, 2016–2026 

Figure 23: Global Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026 

Figure 24: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Live or Attenuated Segment, 2016–2026

Figure 25: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Inactivated or Killed Segment, 2016–2026

Figure 26: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Toxoid Vaccine Segment, 2016–2026

Figure 27: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Conjugate Vaccine Segment, 2016–2026

Figure 28: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Subunit Vaccine Segment, 2016–2026

Figure 29: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Recombinant Vaccine  Segment, 2016–2026

Figure 30: Global Paediatric Vaccine Market Share Analysis (%) By Vaccine Type, 2016 & 2026

Figure 31: Global Paediatric Vaccine Market Y-o-Y Growth (%) By Vaccine Type, 2016–2026 

Figure 32: Global Paediatric Vaccine Market Attractiveness Analysis By Vaccine type, 2016–2026 

Figure 33: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Monovalent Segment, 2016–2026

Figure 34: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Multivalent  Segment,  2016–2026

Figure 35: Global Paediatric Vaccine Market Share Analysis (%) By End Users, 2016 & 2026

Figure 36: Global Paediatric Vaccine Market Y-o-Y Growth (%) By End Users, 2016–2026 

Figure 37: Global Paediatric Vaccine Market Attractiveness Analysis By End Users, 2016–2026 

Figure 38: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Hospital Pharmacy Segment, 2016–2026

Figure 39: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Retail Pharmacy Segment, 2016–2026

Figure 40: Global Paediatric Vaccine Market Absolute $ Opportunity (US$ Mn) By Institutional Health Centres Segment, 2016–2026

Figure 41: North America Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 42: North America Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 43: North America Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 44: North America Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 45: North America Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 46: North America Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 47: North America Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 48: Latin America Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 49: Latin America Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 50: Latin America Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 51: Latin America Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 52: Latin America Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 53: Latin America Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 54: Latin America Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 55: Eastern Europe Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 56: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 57: Eastern Europe Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 58: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 59: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 60: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 61: Eastern Europe Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 62: Western Europe Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 63: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 64: Western Europe Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 65: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 66: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 67: Western Europe Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 68: Western Europe Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 69: Asia Pacific Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 70: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 71: Asia Pacific Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 72: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 73: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 74: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 75: Asia Pacific Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 76: Japan Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 77: Japan Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 78: Japan Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 79: Japan Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026

Figure 80: Middle East and Africa Paediatric Vaccine Market Share Analysis (%) By Country, 2016 & 2026

Figure 81: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Country, 2016–2026

Figure 82: Middle East and Africa Paediatric Vaccine Market Y-o-Y Growth (%) By Country, 2016–2026

Figure 83: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Technology, 2016–2026

Figure 84: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Vaccine Type, 2016–2026

Figure 85: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By Indication, 2016–2026

Figure 86: Middle East and Africa Paediatric Vaccine Market Attractiveness Analysis By End Users,  2016–2026